Berlin Chemie/A. Menarini

What Berlin Chemie/A. Menarini does

Berlin-Chemie/A. Menarini Kft. is the Hungarian operating subsidiary of the Italian Menarini Group, one of Europe's largest privately-held pharmaceutical conglomerates founded in Florence in 1886. Established in Hungary in 1998, the company develops, manufactures, and markets a dual portfolio of prescription (Rx) and over-the-counter (OTC) consumer healthcare products across eight therapeutic areas: cardiovascular, diabetology, respiratory and allergy, pain management, rheumatology, urology, infectious diseases, and thyroid disorders. Its OTC brands include Anaftin, Espumisan, Ibustar, Ketodex, Lioton Gel, Mezym, and Prostamol Uno, with the latter two reducing prices in July 2025 under a Hungarian Ministry of National Economy agreement.

The company's business model is traditional pharmaceutical commercialization: it sells through Hungarian pharmacies, hospitals, and medical institutions, targeting physicians and pharmacists as primary prescribers while reaching end patients through retail and institutional channels. Pricing is constrained by Hungarian government reimbursement and price-negotiation programs, and the firm is subject to EFPIA Transparency Code reporting, GDPR compliance, and pharmacovigilance monitoring. As a wholly-owned subsidiary within the Menarini Group — which operates in 140 countries — Berlin-Chemie/A. Menarini Kft. sits within the regional Berlin-Chemie structure responsible for Germany and over 30 Central and Eastern European and CIS countries, though the Hungarian entity itself operates solely from its Budapest office.

Revenue is not publicly disclosed. The company employs 101-250 staff in Hungary under the leadership of Dr. Oláh Péter. Distribution combines pharmacy wholesale supply for OTC and retail Rx with direct-to-institution sales for hospital channels. There is no disclosed use of AI/ML, no software platform or APIs, and no technology product offering beyond the pharmaceutical portfolio itself. The company is fundamentally a marketing and distribution arm of a global pharmaceutical brand portfolio, with growth and margin profile dependent on group-level pipeline supply, Hungarian reimbursement policy, and competitive dynamics in CEE OTC markets.

Name

Berlin Chemie/A. Menarini

Legal name

Berlin-Chemie/A. Menarini Kft.

Website

https://berlin-chemie.hu

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

101–250 employees

Short description

Berlin-Chemie/A. Menarini Kft. is the Hungarian subsidiary of Italy's Menarini Group, commercializing prescription and OTC pharmaceutical products across eight therapeutic areas through pharmacies and medical institutions in Hungary.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

akta.pro secondary industries

Men’s Health (OTC Urologic & Sexual Health) (HLAIADAK), Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI)

Keywords

• Prescription pharmaceuticals
• OTC consumer healthcare
• Cardiovascular medications
• Urology therapeutics
• Pharmaceutical manufacturing

Headquarters

HQ city

Budaörs

HQ country

Hungary

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Operations, Others

Revenue model

1. Pharmaceutical product sales: Revenue generated from the sale of prescription pharmaceuticals and over-the-counter (OTC) consumer healthcare products across therapeutic areas including cardiovascular, diabetes, respiratory, pain management, urology, and rheumatology.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Berlin-Chemie/A. Menarini Kft. is the Hungarian subsidiary of the Menarini Group, marketing a dual portfolio of prescription pharmaceuticals (Rx) and OTC consumer healthcare products. The Rx portfolio covers eight therapeutic areas—analgesics, cardiovascular diseases, diabetology, infectious diseases, respiratory/allergy, rheumatology, urology, and thyroid disorders—while the OTC line includes branded consumer products such as Anaftin (oral wound care), Espumisan (bloating relief), Ibustar and Ketodex (pain relief), Lioton Gel (varicose veins), Mezym (digestive enzymes), and Prostamol Uno (prostate health). Distribution is conducted through pharmacies, hospitals, and medical institutions in Hungary and Central/Eastern Europe under the broader Menarini Group network spanning 140 countries.

Product overview

Berlin Chemie/A. Menarini is a pharmaceutical company that operates as a 100% subsidiary of the Menarini Group (Italian pharmaceutical leader founded 1886). The company offers a dual portfolio of prescription pharmaceuticals (Rx) and OTC consumer healthcare products. The Rx portfolio spans eight therapeutic areas including analgesics, cardiovascular, diabetology, infectious diseases, respiratory/allergy, rheumatology, urology, and thyroid treatments. The OTC consumer healthcare portfolio includes branded products such as Anaftin (oral wound treatments), Espumisan (bloating relief), Ibustar and Ketodex (pain relief), Lioton Gel (varicose veins), Mezym (digestive enzymes), and Prostamol Uno (prostate health). The company operates primarily in Germany and over 30 Central and Eastern European and CIS countries, with a focus on improving patient quality of life through innovative medicines.

Differentiator

Problem solved

Functional benefit

Brands

• Anaftin (Baby, Gel, Spray): Product line for mouth ulcers (aphthae) treatment - includes Anaftin Baby, Anaftin Gel, and Anaftin Spray
• Espumisan
• IbuStar
• Ketodex
• Lioton
• Mezym
• Prostamol

Products and services

• Anaftin (Baby Teething, Gel, Spray) Anaftin is an OTC product line for oral minor wounds (aphthae) treatment, available as baby teething gel, regular gel, and spray formulations for consumers and patients with mouth ulcers.
• Espumisan (Emulsion 100mg, Pearls 50ct) Espumisan is an OTC bloating relief product containing simeticone as the active ingredient, available in emulsion and pearl formulations for consumers with digestive gas symptoms.
• Ibustar Ibustar is an OTC ibuprofen-based pain relief medication for treatment of headache, toothache, joint pain, and menstrual pain.
• Ketodex Liquid Stick Ketodex is an OTC analgesic product for pain relief, available in liquid stick format for consumer use.
• Lioton Gel Lioton Gel is an OTC medication for varicose veins (phlebeurysm) and circulatory disorders, providing relief for venous insufficiency symptoms.
• Mezym Mezym is an OTC digestive enzyme supplement to aid digestion, addressing exocrine pancreatic insufficiency (EPI) and digestive disorders.
• Prostamol Uno Prostamol Uno is an OTC medication for benign prostatic hyperplasia (BPH), helping relieve lower urinary tract symptoms (LUTS) associated with prostate enlargement.
• Prescription Pharmaceuticals (Analgesics, Cardiovascular, Diabetes, Infectious Diseases, Respiratory/Allergy, Rheumatology, Urology, Thyroid) Prescription pharmaceutical portfolio spanning eight therapeutic areas: pain management, cardiovascular diseases (angina, hypertension), diabetology, infectious diseases, respiratory conditions (asthma, COPD), rheumatology (gout), urology (BPH, erectile dysfunction), and thyroid disorders. Products are developed, manufactured, and marketed by Berlin-Chemie for physicians and institutional prescribers.

Segments6 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered core.

• Hungarian Government / Nemzetgazdasági MinisztériumcoreOthers · 1 July 2025Berlin-Chemie/A. Menarini Kft., as a member of the Association of Innovative Pharmaceutical Manufacturers (Innovatív Gyógyszergyártók Egyesülete), participated in negotiations with the Hungarian Ministry for National Economy to reduce patient burdens. The company agreed to reduce prices for three key products (Lioton gel, Prostamol Uno, and one prescription medication) starting July 1, 2025, aligning with government efforts to make medications more affordable for Hungarian patients.
• Menarini GroupcoreOthers · 1 January 1992Berlin-Chemie AG was acquired by the Italian Menarini Group in 1992 through an international tender process. Berlin-Chemie has been a 100% owned subsidiary of the Menarini Group since then. The Menarini Group, founded in 1886 in Florence, Italy, is Italy's leading pharmaceutical and diagnostics company with presence in 140 countries.

Scale indicators5 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• KRKA: Slovenian pharmaceutical company with broad Rx and OTC portfolio sold across CEE, CIS, and Western European markets. Comparable as a regional CEE pharma with diversified therapeutic coverage and consumer healthcare brands.
• Gedeon Richter: Hungary's largest pharmaceutical company with branded and generic operations across CEE, Western Europe, and CIS markets. Directly comparable as a Hungary-headquartered pharma with diversified Rx portfolio and CEE regional distribution strength.
• Egis Pharmaceuticals: Hungarian pharmaceutical manufacturer and marketer with broad therapeutic coverage in cardiovascular, CNS, and respiratory areas. Highly comparable as a domestic Hungarian pharma with overlapping primary-care Rx portfolio and CEE market focus.
• Zentiva: Czech-based pan-European generics and OTC pharma company with strong presence across CEE markets. Comparable as a CEE-focused pharma with branded-generic and consumer healthcare products distributed across overlapping geographies.
• STADA Arzneimittel: German-headquartered pharma company specializing in generics, OTC, and consumer healthcare across European markets. Comparable as a CEE-strong OTC/generics player with branded consumer health products like Menarini's portfolio.

Broad incumbents

• Teva Pharmaceutical: Global pharmaceutical company with significant CEE operations and broad generics/specialty portfolio. Comparable as a large incumbent operating across CEE with both Rx and consumer health offerings.
• Sanofi: Global pharmaceutical major with strong consumer healthcare (OTC) franchise and significant CEE presence. Comparable as a large incumbent with branded Rx and OTC across overlapping therapeutic and geographic markets.
• Menarini Group: Italian parent company of Berlin-Chemie, Italy's leading pharmaceutical group operating in 140 countries with branded Rx and OTC. Directly comparable as the parent with substantially overlapping portfolio and broader geographic footprint.
• Bayer: Global pharmaceutical and consumer health company with cardiovascular and OTC portfolios (e.g., cardiovascular, pain, consumer care). Comparable as a broad incumbent operating across CEE with primary-care and consumer health products.

Regional players

• Alkaloid: North Macedonian pharmaceutical company with branded Rx, OTC, and consumer health products distributed across CEE and SEE markets. Comparable as a regional pharma player with overlapping primary-care therapeutic focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Berlin Chemie/A. Menarini